SELLAS Life Sciences Group, Inc. — Director's Dealing 2010

Jan 22, 2010

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RXI PHARMACEUTICALS CORP (RXII)
CIK: 0001390478
Period of Report: 2010-01-20

Reporting Person: Beerman Noah D (Director, CEO and President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2010-01-20	Common Stock	A	5407	$0.00	Acquired	5407	Direct

Footnotes

F1: The Common Stock reported on this Form 4 represent restricted stock units with a contingent right to receive one share RXII common stock for each restricted stock unit and the vesting will be determined by the Company. Such grant was made in lieu of a cash bonus.